Mesenchymal Stem Cell Therapy for Multiple System Atrophy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for multiple system atrophy (MSA) are ineffective in halting disease progression, and there is a need for neuroprotective or regenerative strategies to manage this progressive neurodegenerative disorder.

Innovation Solution

Administering a therapeutically effective amount of mesenchymal stem cells (MSCs) via intra-arterial injection and repeated intravenous injections to patients with MSA, utilizing autologous MSCs derived from bone marrow, which are isolated, purified, and expanded in culture for delivery to the brain.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional drug treatments are used for MSA patients, then treatment is simple to administer, but the treatments are ineffective in halting disease progression

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidcomplexity of treatment approach

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses mesenchymal stem cells (MSCs) as intermediary agents to deliver neuroprotective effects. The MSCs are isolated from bone marrow, expanded in culture, and administered to patients to mediate the therapeutic effect of delaying neurological deficit progression and improving functional outcomes.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Duration of action of stationary object

If neuroprotective or regenerative strategies are implemented, then disease progression may be slowed, but the treatment approach becomes more complex

Engineering Contradiction:

Improveduration of disease progression delayVSAvoidcomplexity of cell therapy process

Core Design Contradiction:

Duration of action of stationary objectVSDevice complexity

Solution Approach 1:

The patent applies preliminary action by isolating and expanding mesenchymal stem cells in culture before administration. The cells are prepared in advance, multiplied to therapeutic doses, and then administered to patients, allowing the regenerative effect to take place over an extended period rather than requiring immediate high-dose intervention.

Inventive Principle:

Principle #10Preliminary action

3Ease of operation

If MSC therapy is administered via intra-arterial and intravenous injection, then functional improvement is achieved, but the administration process becomes more complex

Engineering Contradiction:

Improveease of patient treatmentVSAvoidcomplexity of injection protocol

Core Design Contradiction:

Ease of operationVSDevice complexity

Solution Approach 1:

The patent segments the administration process into two distinct routes: intra-arterial injection for direct cerebral delivery and repeated intravenous injections for systemic distribution. This segmentation allows optimization of each route's advantages while managing the overall complexity through standardized protocols for each injection type.

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS8637003B2Treating multiple system atrophy with hMSC

Publication Date: 2014.01.28 AJOU UNIV IND ACADEMIC COOP FOUND

AI summary

The present invention provides a method for treating multiple system atrophy, comprising administering a therapeutically effective amount of mesenchymal stem cells (MSCs) to a human in need thereof. Preferably, the administering is performed by an intra-arterial injection of said MSCs and one or more intravenous injections of said MSCs.